How does a single-agent immunocytokine compare to standard co-administration research (e.g., αPD-L1 antibody plus N-803)?

Our single-agent αPD-L1 immunocytokine is preclinically proven to be superior. Its single-molecule design facilitates superior TME penetration and retention, uniquely upregulates chemokine receptors for enhanced immune cell trafficking, and provides the triple action of checkpoint inhibition, IL-15 signaling, and ADCC.

What types of toxicity does the proprietary concealment engineering help mitigate in the IL-15 component?

The primary concern with systemic IL-15 is widespread, non-specific proliferation of NK cells and T-cells in the periphery, leading to cytokine release syndrome and vascular leak. Our concealment engineering physically interrupts IL-15 binding to peripheral cells, thereby minimizing systemic cytokine-related toxicity and directing the signaling exclusively to the tumor site.

PD-1/PD-L1 integrated IL-15 Combination Therapy Service

Creative Biolabs provides expert molecular engineering and preclinical validation of next-generation immunotherapies. We offer two key strategies-PD-1 cis-delivery and αPD-L1 targeting create a single-agent fusion protein that simultaneously blocks checkpoints and stimulates T-cells via IL-15. Our clients can expect to gain a highly potent, low-toxicity drug lead, complete with robust QC, PK/PD modeling, and comprehensive in vivo efficacy data suitable for advanced preclinical development.

Introduction What We Can Offer Workflow Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us

Introduction of PD-1/PD-L1 Integrated IL-15 Combination Therapy Service

The synergy between checkpoint blockade and immune stimulation is the critical factor for overcoming cancer immune evasion. Cited literature confirms that PD-1/PD-L1 inhibitors often require combination partners, with Interleukin-15 (IL-15) superagonists offering potent CD8⁺ T-cell and NK cell expansion. Creative Biolabs' service capitalizes on this by engineering concealed, single-molecule agents, such as αPD-L1 immunocytokines. These constructs demonstrate superior TME remodeling, reduced systemic toxicity, and enhanced efficacy compared to co-administered drugs. This approach defines the next generation of targeted cancer research tools by providing both the brake release and the immunological fuel.

What We Can Offer

Customized Dual-Strategy Implementation

We offer customized fusion protein design, allowing you to choose and optimize between the PD-1 cis-delivery approach (for T-cell rejuvenation) or the αPD-L1 immunocytokine platform (for superior TME remodeling and ADCC).

Proprietary Concealment Engineering

Our unique linker technology is engineered to minimize systemic exposure, ensuring the IL-15 superagonist is biologically inactive until it reaches the tumor site, drastically reducing cytokine-related toxicity and vascular leak risk.

Synergistic Efficacy Benchmarking

We validate that your engineered single-agent molecule is superior to the equivalent co-administered drug combination, providing compelling evidence of true synergy to support your research filings.

Advanced TME Remodeling Analysis

We go beyond simple tumor volume data, providing in-depth analysis of key suppressive cell populations (e.g., Treg and MDSC reduction) and crucial chemokine upregulation for enhanced immune cell trafficking.

How Creative Biolabs Can Help

Why Choose Us?

Core Advantages	Unique Features
Customized Precision	We offer customized fusion protein engineering, allowing optimization of either PD-1 cis-delivery or αPD-L1 immunocytokine targeting. This includes advanced analysis of TME remodeling and enhanced immune cell trafficking for optimal design.
Reduced Systemic Risk	Our proprietary Concealment Engineering uses unique linker technology to minimize systemic exposure. This ensures the potent IL-15 payload remains inactive until it reaches the tumor, drastically reducing off-target cytokine-related toxicity and vascular leak risk.
Benchmarked Synergy	We validate your single-agent molecule's synergistic superiority compared to standard co-administered drugs. This provides compelling evidence of enhanced T-cell expansion and potent suppression of T-regulatory and myeloid-derived suppressor cells (MDSC) in your models.

Core Advantages

Unique Features

Customized Precision

We offer customized fusion protein engineering, allowing optimization of either PD-1 cis-delivery or αPD-L1 immunocytokine targeting. This includes advanced analysis of TME remodeling and enhanced immune cell trafficking for optimal design.

Reduced Systemic Risk

Our proprietary Concealment Engineering uses unique linker technology to minimize systemic exposure. This ensures the potent IL-15 payload remains inactive until it reaches the tumor, drastically reducing off-target cytokine-related toxicity and vascular leak risk.

Benchmarked Synergy

We validate your single-agent molecule's synergistic superiority compared to standard co-administered drugs. This provides compelling evidence of enhanced T-cell expansion and potent suppression of T-regulatory and myeloid-derived suppressor cells (MDSC) in your models.

To fully understand the Creative Biolabs advantage, contact us to discuss your needs.

Customer Reviews

FAQs

Related Services

IL-15 driven Multispecific Immune Engager Engineering Service

Specialized engineering and design of IL-15-armed multispecific antibodies (e.g., Bi- or Tri-specific T-cell engagers) to enhance T-cell recruitment, activation, and persistence against complex tumor targets.

Learn More →

IgG-Scaffolded IL-15 Tumor Targeting Service

Development of non-checkpoint targeted immunocytokines using a standard IgG backbone fused with IL-15 superagonist, optimizing for Fc binding and selective tumor antigen recognition.